Harnessing RNA sequencing to confirm highly different expressions of Glypican 2 (GPC2) across multiple pediatric brain tumors, researchers designed GPC2-directed CAR-T cells that could safely target malignant tumors with local delivery [107]. This evidence concerns the gene GPC2 and brain neoplasm.